GLP-1/glucagon receptor co-agonism for treatment of obesity
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies. The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications. Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance. Pharmacological attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body weight. Novel unimolecular, multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body weight. In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacologically function at the receptors for glucagon and glucagon-like peptide-1. Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is achieved by enhancing the metabolic rate through the stimulation of hepatic glucose production and activating thermogenic pathways in brown adipose tissue [31].”
From Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials (2026) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work primarily by increasing energy expenditure and promoting weight loss independently of GLP‐1‐mediated appetite suppression.”
From Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials (2026) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“Combining both glucagon receptor and GLP-1 receptor agonism in a single molecule could target weight loss through multiple mechanisms of action to enhance the level of weight loss possible [18].”
In the citing paper
“Since the activation of these pathways sometimes produces opposite effects, the concurrent action on two or more of them could result in a complementary and synergistic effect [154].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Similarly, recent long-term studies of liraglutide and semaglutide, focusing on cardiovascular outcomes in individuals with type 2 diabetes, reveal a similar incidence of pancreatitis between groups treated with the GLP-1R agonists and placebo [31, 41].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Similarly, recent long-term studies of liraglutide and semaglutide, focusing on cardiovascular outcomes in individuals with type 2 diabetes, reveal a similar incidence of pancreatitis between groups treated with the GLP-1R agonists and placebo [31, 41].”
BackgroundGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 1×
“5% of the global population) [4] and this number is expected to rise to 592 million by 2035 [5].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“cially in response to meals high in fat and carbohydrates [14].”
BackgroundInfluentialLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“In this regard, clinical study of lixisenatide in individuals with type 2 diabetes and acute coronary syndrome did not reveal an association with pancreatitis [40].”
BackgroundChang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688 · cited 1×
“At the other extreme, bariatric surgeries are highly effective in reducing body weight and improving glucose tolerance in most individuals [7, 8].”
BackgroundMedical Consequences of Obesity
Bray, G. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0535 · Cited by 1,538
Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422 · cited 1×
“hyperleptinaemic, develop central leptin resistance and are unresponsive to leptin therapy [72].”
BackgroundPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 2×
“However, these therapies are commonly accompanied by adverse gastrointestinal and cardiovascular effects that limit their use [12].”
Background
Research works printed but not linked: 2
- Roglic G World Health Organization Global report on diabetes 2016 Geneva World Health Organization
- Lao J Hansen BC Dimarchi R Pocai A Effect of GLP1R/GCGR dual agonist in monkeys Diabetes 2013 62 A257 A257
Cited by
Items 101–188 of 188
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 14
Wang, M.-W., & Lu, L. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00271 · Cited by 17
“103 Moreover, GCGR is expressed in the liver and shows direct hepatic benefits, including a reduction in lipid content and an increase in metabolic expenditure.”
Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes
Eriksson, O., Velikyan, I., Haack, T., Bossart, M., Laitinen, I., Larsen, P. J., Berglund, J. E., Antoni, G., Johansson, L., Pierrou, S. E., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213306 · Cited by 13
Shah, M. A., Haris, M. N., Faheem, H. I., Hamid, A., Yousaf, R., Rasul, A., Shah, G. M., Khalil, A. A. K., Wahab, A., Khan, H. Z., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220628123224 · Cited by 14
Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
Vishnoi, S., Bhattacharya, S., Walsh, E. M., Okoh, G., & Thompson, D. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00752 · Cited by 14
D‐Ser2‐oxyntomodulin ameliorated Aβ31‐35‐induced circadian rhythm disorder in mice
Wang, L., Zhao, J., Wang, C., Hou, X., Ning, N., Sun, C., Guo, S., Yuan, Y., Lin, L., Hölscher, C., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13211 · Cited by 13
Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
Eriksson, O., Velikyan, I., Haack, T., Bossart, M., Evers, A., Laitinen, I., Larsen, P. J., Plettenburg, O., Takano, A., Halldin, C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51530-0 · Cited by 11
Han, C., Sun, Y., Yang, Q., Zhou, F. L., Chen, X., Wu, L., Sun, L., & Han, J. D. J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00995 · Cited by 12
Jiang, N., Su, D., Chen, D., Huang, S., Tang, C., Jing, L., Yang, C.-Y., Zhou, Z., Yan, Z., & Han, J. D. J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01049 · Cited by 10
Mechanisms of drugs in the treatment of type 2 diabetes mellitus
Yang, T., Wang, H., Li, C., & Duan, H. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002356 · Cited by 12
“[20,21] The AMP-activated kinase (AMPK) acts as an energy-sensing glucose, fat, and other tissue oxidized fatty acids, and reduces hepatic glucose production.”
Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist
Gibadullin, R., Cary, B. P., & Gellman, S. H. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01628 · Cited by 10
Blind De Novo Design of Dual Cyclic Peptide Agonists Targeting GCGR and GLP1RPreprint
Li, Q., Wiita, E., Helleday, T., & Bryant, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.06.658268 · Cited by 10
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Graham, G. V., McCloskey, A. G., Abdel‐Wahab, Y. H. A., Conlon, J. M., & Flatt, P. R. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110584 · Cited by 10
Conlon, J. M., O'Harte, F. P. M., & Flatt, P. R. (2021) · Peptides · doi:10.1016/j.peptides.2021.170706 · Cited by 9
Graham, G. V., Conlon, J. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.011 · Cited by 9
Gastrointestinal peptides and nonalcoholic fatty liver disease
Tarantino, G., & Balsano, C. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000514 · Cited by 9
“It should be stressed that several phase 1 or 2 clinical studies using glucagon/GLP-1 receptor dual agonists and glucagon/GIP/GLP-1 receptor triple agonists are being conducted in human obese diabetic patients [19].”
BackgroundAlluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Gpr149 is involved in energy homeostasis in the male mouse
Wyler, S. C., Surbhi, Cao, N., Merchant, W., Bookout, A. L., & Gautron, L. (2024) · PeerJ · doi:10.7717/peerj.16739 · Cited by 12
The role of glucagon after bariatric/metabolic surgery: much more than an “anti-insulin” hormone
Pérez-Arana, G.-M., Díaz-Gómez, A., Reyes, J. B.-D. L., Romero, M. Á. G., Ribelles-García, A., Visiedo, F., González‐Domínguez, Á., Gomar, D. A., & Oliveira, J. A. P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236103 · Cited by 8
Huh, K. Y., Hwang, J. G., Shin, W., Baek, S. J., Choi, J., Lee, N., Cho, Y. M., & Lee, H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14590 · Cited by 8
“leucine, lysine) amino acids (Figures 1E,F, S9, and S10).(27) On the other hand, the comparatively small changes in cholesterol levels could have been attributable to the comparatively short duration of the study.”
BackgroundFrom Entero-Endocrine Cell Biology to Surgical Interventional Therapies for Type 2 Diabetes
Guimarães, M., Pereira, S. S., & Monteiro, M. P. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_480 · Cited by 9
Shankar, K., Ramborger, J., Bonnet-Zahedi, S., Carrette, L. L. G., & George, O. (2023) · Hormones and Behavior · doi:10.1016/j.yhbeh.2023.105447 · Cited by 7
Designer GLP1 poly-agonist peptides in the management of diabesity
Statham, L., Pelling, M., Hanson, P., Kyrou, I., Randeva, H. S., & Barber, T. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204976 · Cited by 8
“resource and relative invasiveness of bariatric surgery [78].”
BackgroundLi, X., & Petrov, M. S. (2024) · Nutrients · doi:10.3390/nu16030435 · Cited by 7
Specific Activity of Recombinant Modified Human Glucagon-Like Peptide 1
Sannikova, E. P., Bulushova, N. V., Cheperegin, S. E., Zalunin, I. A., Klebanov, F. A., Gracheva, T. S., Yurin, V. L., Rykalina, N. V., Askerova, E. V., Yarotskii, S. V., et al. (2019) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683819070068 · Cited by 8
Zhang, W., Shen, D., Li, Y., Zhong, H., Wang, X., Cui, X., Shi, C., Ji, C., Guo, X., & Chen, L. (2019) · Nutrition & Metabolism · doi:10.1186/s12986-019-0414-z · Cited by 6
Wagner, M., Doverfjord, J. G., Tillner, J., Antoni, G., Haack, T., Bossart, M., Laitinen, I., Johansson, L., Pierrou, S. E., Eriksson, O., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13080176 · Cited by 6
Jiang, W., Skoug, C., Rodrigues, I., Ciabatti, E., Gribble, F. M., Reimann, F., Brierley, D. I., Holt, M. K., & Trapp, S. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102347 · Cited by 5
“This could be improved by combining PPG neuron activation with drugs which augment energy expenditure such as glucagon receptor agonists [35].”
Khator, R., Singh, Y., Asati, V., & Monga, V. (2024) · ChemistrySelect · doi:10.1002/slct.202400322 · Cited by 5
Repanovici, A., Rogozea, L. M., & Pantea, I. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001805 · Cited by 7
Pharmacological treatments for adults with overweight and obesity without diabetes
Shang, W., Xu, H., Li, M., Ren, J., Huang, X., Li, J., Wang, X., Wang, Q., Ma, Y., Madrid, E., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015861 · Cited by 7
Camins, A., Ettcheto, M., Busquets, O., Manzine, P. R., Castro-Torres, R. D., Beas‐Zárate, C., Verdaguer, E., Sureda, F. X., Bulló, M., Olloquequi, J., et al. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1552677 · Cited by 5
“The pharmacological combination of GLPI/GIP/Glucagon receptor triagonist prevented the decline of brain glucose metabolism and significantly reduced obesity [26].”
BackgroundDutta, D., Kamrul-Hasan, A. B. M., Joshi, A. S., Dhall, A., Nagendra, L., & Sharma, M. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_366_24 · Cited by 4
“[18,19] The anti‑obesity and anti‑hyperglycaemic outcomes of survodutide 2.4 mg/week compare impressively to other dual agonists for the glucagon‑like peptide 1 receptor (GLP‑1R) and the glucagon receptor (GCGR) under development like mazdutide and cotadutide.”
InfluentialWu, B., Falsey, J. R., Netirojjanakul, C., Herberich, B., Holder, J. R., Sham, K. K. C., Aral, J., Forsythe, N., Walker, K. W., Lu, S.-C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00032 · Cited by 4
Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
Anderson, S. L. (2025) · Drugs in Context · doi:10.7573/dic.2025-4-8 · Cited by 4
Promising areas of pharmacotherapy for obesity
Druzhilov, М. A., Kuznetsova, Т. Y., & Chumakova, G. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4279 · Cited by 4
Chepurny, O. G., Matsuokas, M.-T., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.aac119.009193 · Cited by 4
Abulehia, A., Ayesh, H., Ayesh, O., Jaber, D., Asad, T., Itbaisha, A., Abugharbieh, H., Gharbia, R., Abu‐Hilal, L. H., & Leon, B. G. C. (2026) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70187 · Cited by 3
“This is achieved by enhancing the metabolic rate through the stimulation of hepatic glucose production and activating thermogenic pathways in brown adipose tissue [31].”
Huang, Y., Rupnik, M. S., & Rutter, G. A. (2026) · Communications Biology · doi:10.1038/s42003-026-10163-6 · Cited by 3
“These fi ndings are consistent with previous reports demonstrating that chronic glucagon agonism 49 , or glucagon and GLP-1 co-agonism 50 , exerts antidiabetogenic effects in mice through whole-body metabolic mechanisms, including greater weight loss and improved glucose metabolism.”
Hitaka, K., Sugawara, T., Matsumoto, M., & Nio, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02025-2 · Cited by 3
“These GLP-1 analogs affect glucose-dependent insulinotropic polypeptide receptors and glucagon receptors, in addition to GLP-1R and are expected to exhibit stronger anti-obesity effects than that of semaglutide [21, 22].”
Cantini, G., Trabucco, M., Dicembrini, I., Mannucci, E., & Luconi, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00016-x · Cited by 3
Shin, W., Hompesch, M., Byeon, J., Kang, S., Choi, J., & Baek, S. J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15162 · Cited by 3
“Recent studies have also shown that glucagon plays a central role in the regulation of lipid metabolism, energy expenditure and satiety regulation,(4) which implies that it may have a potential role in obesity management; this theory is supported by the fact that glucagon displays co-agonism with glucagon-like peptide…”
BackgroundMédicaments anti-obésité : leçons des échecs pour l’avenir
Scheen, A. J. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.012 · Cited by 4
Iyer, S., Montmayeur, J., Zolotukhin, S., & Dotson, C. D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110408 · Cited by 2
Filha, A. M. S. G., Leite, J. M., Lagares, L. S., de Jesus, D. S., Bomfim, E. S., de Almeida, L. A. B., Pinto, L. L. T., de Souza, L. A. J., & dos Santos, C. P. C. (2025) · Brazilian Journal of Kinanthropometry and Human Performance · doi:10.1590/1980-0037.2025v27e103939 · Cited by 5
Observation of unique stable nano-assemblies of a lipidated glucagon-like peptide 1 analogue
Brichtova, E. P., dos Santos, A. L. G., & Jackson, S. (2025) · Soft Matter · doi:10.1039/d5sm00801h · Cited by 2
“2 The additional therapeutical benefits of GLP-1-based analogues include weight reduction 3,4 and even lowering of cardiovascular disease risks.”
Tang, X., Chen, H., Zhang, G., Li, H., Zhao, D., Bi, Z., Wang, P., Zhou, J., Chen, S., Cong, Z., et al. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60969-1 · Cited by 4
The GLP ‐1– miRNA network: Epigenetic control of obesity and metabolic disorders
Zhao, S., Qin, P., Wang, X. F., & You, Q. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70551 · Cited by 2
“91 Beyond dual and triple agonists, multi-agonist strategies are emerging that simultaneously target additional gut-derived hormones, including PYY and OXM, to create an integrated metabolic network.”
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
“Combining GIP activity with GLP-1 and glucagon receptor agonists might enhance weight loss and glycemic control while also lowering the risk of diabetes from chronic glucagon receptor activation [186–188].”
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“GLP-1 counteracts the hyperglycemic effects of GCG primarily by stimulating glucose-dependent insulin secretion, while suppressing glucagon release in a glucose-dependent manner [78].”
Regulation of Appetite and Satiety by Gastrointestinal Peptides
Mhaibes, S. H., Fakree, N. K., & Naser, S. E. (2021) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol30iss1pp14-21 · Cited by 4
Xu, L., Hu, R., Jois, S. V., & Zhang, L. (2023) · PeerJ · doi:10.7717/peerj.15705 · Cited by 2
Bolze, F., Williams, H., Bhuwania, R., Egecioglu, E., Bloem, E., Paulsson, J. F., Pedersen, M. Ø., Broadmeadow, A., Chesher, C. J., Moore, E. L., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115152 · Cited by 2
GLP-1 Is Not Enough: Can Glucagon Fill the Energy Expenditure Gap?
Beji, S., & Caron, A. (2026) · Neuroendocrinology · doi:10.1159/000550812 · Cited by 1
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism
Saldívar-Cerón, H. I., Maldonado-Trejo, D., Chavez-Castañeda, Q., Mercado-Guzmán, A. L., León-Barrita, A. D. J., López-García, I. A., Hernández-Solís, A., Ramírez-Mendoza, A. M., Terrazas-Delgado, D. A., Castañeda-Ramírez, A. E., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219654 · Cited by 1
Peptide-Based Regulation of Metabolism as Related to Obesity
Bergen, W. G. (2017) · Endocrinology · doi:10.1210/en.2017-00696 · Cited by 1
Nedyalkova, M., Robeva, R. N., Romanova, J., Yovcheva, K., Lattuada, M., & Simeonov, V. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2330714 · Cited by 1
“One example is the treatment of type 2 diabetes mellitus (T2DM) and obesity using glucagon and glucagon-like peptide-1 (GLP-1) receptors (Ambery et al., 2018; S � anchez-Garrido et al., 2017).”
Novas terapias para obesidade: eficácia e segurança dos agonistas de GLP-1
Gonçalves, F. S., & Lima, A. R. L. R. (2025) · Research Society and Development · doi:10.33448/rsd-v14i1.48004 · Cited by 3
Eriksson, O., Hockings, P. D., Johansson, E., Johansson, L., & Kullberg, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_7
Zhang, Q., Zhang, X., & Niu, C.-Y. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i11.393
Effect of Incretogenic Peptides on Non-Alcoholic Fatty Liver Disease
苏, 怡. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361396
Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care
Gnanathayalan, S. W., & Sumanatilleke, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_110_23
Chepurny, O. G., Liles, A. N., Cham, N., Matsoukas, M., Liapakis, G., Meng, Q., Cooney, R. N., Doyle, R. P., & Holz, G. G. (2025) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2025.114745
N-glycosylation effects on the function of class B1 G protein-coupled receptors
Lee, S. M., Jin, J., Song, H., & Jang, J. (2025) · Carbohydrate Research · doi:10.1016/j.carres.2025.109641
Lai, W., Peng, L., Min, J., Qiu, L., Wang, C., Yu, S., Li, Q., Li, R., Jiang, X., & Chen, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1665860
“Moreover, recent studies suggest that dual GCGR/GLP-1R agonists may have stronger pharmacological effects than single agonists (9).”
Effects of diet, exercise and anti-obesity treatment on adult neural stem cells and neurogenesis
Jörgensen, S. K. M. (2024) · ORCA Online Research @Cardiff (Cardiff University)
Fekri-Kourabbaslou, V., Amirsasan, R., & Nikoukheslat, S. D. (2026) · Health Science Reports · doi:10.1002/hsr2.72204
Diabetic nephropathy: pathophysiology, biomarkers and treatment strategies
Singh, A., Maheshwari, S., Kumar, P., Agrahari, M., & Singh, A. K. (2026) · Journal of The Egyptian Society of Nephrology and Transplantation · doi:10.4103/jesnt.jesnt_2_26
Mahmood, A., Sehar, N. U., Farooq, A., Latif, S., Rasul, M., Abbasi, S., Ali, A. M., Arshad, E., Malik, M. A., Nenwani, K., et al. (2026) · F1000Research · doi:10.12688/f1000research.186694.1
Sanchez-Navarro, M. J., Zhang, C., Schmidt, H. D., & Hayes, M. R. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115478
ANÁLOGOS DO GLP-1 NO TRATAMENTO DA INFERTILIDADE EM MULHERES COM SOP: Uma revisão de escopo
Butzen, M. C., Ribeiro, L. M., Ledesma, A. G. W., & Dadalt, M. L. R. (2026) · Brazilian Medical Students · doi:10.53843/bms.v11i15.1432
Duale und triagonistische Inkretine: Stand und Einfluss auf die MASLD
Kirchhoff, M., & Schattenberg, J. M. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-01015-0
Tekieli, B., Cyran, W. K., Matsiusheuskaya, T., Cionżyńska, W., Machnik, K., Gaweł, B., Justkowska-Gebauer, A., Olesiński, M., Chudyba, E., & Górecki, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6110
“By simultaneously activating complementary incretin pathways, these agents may provide broader metabolic and neuroprotective effects than GLP-1 receptor agonist monotherapy (Fukuda, 2021; Sánchez-Garrido et al., 2017).”
ALNAWMASI, M. S., Albalawi, W. S., Hayyan, M. Y., ALHARBI, M. S. S., & ALOTAIBI, M. A. R. (2025) · TPM Testing, psychometrics, methodology in applied psychology
Ramasinghe, C., & Xu, B. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.105166
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
BindingDB Entry 50012137: Stapled and
BindingDB (2022) · UC San Diego · doi:10.7270/q25h7kx4
Metadata
- Authors
- Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H.
- Affiliations
- Helmholtz Munich (DE)
- Indiana University Bloomington (US)
- Corresponding author
- DiMarchi, Richard D.
- Tschöp, Matthias H.
- Venue
- Diabetologia
- Published
- 2017-07-21
- Volume
- 60
- Issue
- 10
- Pages
- 1851-1861
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6448809
- OpenAlex
- W2737611067
- Cited by
- 175
- References
- 97
- Citations by year
- 2026: 19 · 2025: 15 · 2024: 13 · 2023: 22 · 2022: 15 · 2021: 23 · 2020: 17 · 2019: 25 · 2018: 23 · 2017: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion, other-oa)
- Funders
- Alexander von Humboldt-Stiftung
- Lundbeckfonden (R210-2015-4001)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor, glucagon receptor, dual agonist, obesity, type 2 diabetes, anti-obesity drugs, peptide therapeutics, polypharmacy, bariatric surgery, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Humans, Obesity, Receptors, Glucagon, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.